FDA granted regular approval to pembrolizumab (KEYTRUDA, Merck and Co., Inc.) for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. May 18, 2017. More Information: https://www.fda.gov/Drugs/
viernes, 19 de mayo de 2017
Approved Drugs > Pembrolizumab (Keytruda): Advanced or Metastatic Urothelial Carcinoma
Approved Drugs > Pembrolizumab (Keytruda): Advanced or Metastatic Urothelial Carcinoma
![fda header](https://blogger.googleusercontent.com/img/proxy/AVvXsEgJOwS6ZimiVzTWCq6E_5yPtmyGtZvMkci3ukoh_E-Yh4XOLPbQEyXX6hQPasunoRZKeEWswWUDo9tTFxGJaLEgrCp-xKwBcBbBOIfWINw6gxjV_TAcjF-dIoJXK0Xs3Ms737FfQIdPDS0R-RgKc5_iR78OWzOwTqVmG_0m2E7Us0vzOlIkAYPuh2LpoRHP_JpEBGIGQ3Sr4YItMx1IRGVDanSLgG_Grvs=s0-d-e1-ft)
FDA granted regular approval to pembrolizumab (KEYTRUDA, Merck and Co., Inc.) for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. May 18, 2017. More Information: https://www.fda.gov/Drugs/ InformationOnDrugs/ ApprovedDrugs/ucm559300.htm
FDA granted regular approval to pembrolizumab (KEYTRUDA, Merck and Co., Inc.) for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. May 18, 2017. More Information: https://www.fda.gov/Drugs/
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario